HIGHLIGHTS
- who: Vesna Vetma from the National Center for Tumor Diseases (NCT), Dresden, Germany have published the article: Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism, in the Journal: (JOURNAL)
- what: The authors demonstrate that a novel and translationally relevant hexavalent TRAIL receptor agonist IZI1551 in combination with Birinapant a clinically tested IAP antagonist efficiently induces cell death in various melanoma models and that responsiveness can be predicted by combining pathway analysis data-driven modelling and pattern recognition. The authors performed LOOCV based on the approach described . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.